Country: United States
Language: English
Source: NLM (National Library of Medicine)
RISPERIDONE (UNII: L6UH7ZF8HC) (RISPERIDONE - UNII:L6UH7ZF8HC)
WOCKHARDT USA LLC.
RISPERIDONE
RISPERIDONE 1 mg in 1 mL
ORAL
PRESCRIPTION DRUG
Adults Risperidone oral solution is indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)]. Adolescents Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. Pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for Janssen Pharmaceuticals Corporation’s risperidone drug products. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone. Therefore, risperidone is contraindicated in patients with a known hypersensitivity to the product.
Risperidone Oral Solution Risperidone 1 mg/mL Oral Solution (NDC 64679-692-01) is supplied in 30 mL bottles with a calibrated (in milligrams and milliliters) syringe. The minimum calibrated volume is 0.25 mL, while the maximum calibrated volume is 3 mL. Storage and Handling Risperidone 1 mg/mL Oral Solution should be stored at 200 -250 C (680 -770 F) [See USP Controlled Room Temperature]. Protect from light and freezing. Keep out of reach of children
Abbreviated New Drug Application
RISPERIDONE - RISPERIDONE SOLUTION WOCKHARDT USA LLC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RISPERIDONE ORAL SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RISPERIDONE ORAL SOLUTION. RISPERIDONE ORAL SOLUTION FOR ORAL USE. INITIAL U.S. APPROVAL:1993 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING. ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. RISPERIDONE IS NOT APPROVED FOR PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (5.1) RECENT MAJOR CHANGES Boxed Warning 08/2008 Warnings and Precautions (5.1) 08/2008 Warnings and Precautions, Leucopenia, Neutropenia, and Agranulocytosis (5.8) 09/2009 INDICATIONS AND USAGE Risperidone is an atypical antipsychotic agent indicated for: (1) Treatment of schizophrenia in adults (1.1) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults (1.2) Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia, bipolar mania or autistic disorder.(1.1,1.2,1.3) (1) DOSAGE AND ADMINISTRATION INITIAL DOSE T ITRATIO N TARGET DOSE EFFECTIVE DOSE RANGE Schizophrenia – adults (2.1) 2 mg/day 1 to 2 mg daily 4 to 8 mg daily 4 to 16 mg / day Bipolar mania- adults (2.2) 2 to 3 mg / day 1 mg daily 1 to 6 mg / day 1 to 6 mg / day DOSAGE FORMS AND STRENGTHS Oral solution: 1 mg/mL (3) CONTRAINDICATIONS Known hypersensitivity to the product (4) WARNINGS AND PRECAUTIONS (5) Cerebrovascular events, including stroke, in elderly patients with dementia-related psychosis. Risperidone is not approved for use in patients with dementia-related psychosis (5.2) Neuroleptic Malignant Syndrome (5.3) Tardive dyskinesia (5.4) Hyperglycemia and diabetes mellitus ( Read the complete document